ABT-436
Chemical compound
From Wikipedia, the free encyclopedia
ABT-436 is an orally active, highly selective vasopressin V1B receptor antagonist which was under development by Abbott Laboratories and AbbVie for the treatment of major depressive disorder, anxiety disorders, and alcoholism but was discontinued.[1][2][3] It reached phase II clinical trials prior to the discontinuation of its development.[1][3]
| Clinical data | |
|---|---|
| Routes of administration | By mouth |
| Identifiers | |
| CAS Number | |
| PubChem SID | |
